Our Program Areas
Temperature Stable Tuberculosis Vaccine
Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, disproportionately affecting low-resource communities where cold-chain logistics are challenging. At AAHI, we’re addressing this gap with ID93+GLA-SE—a next-generation, temperature-stable TB vaccine designed for global accessibility.
Spray-Dried Vaccine Platform
Our spray-dry platform turns liquid vaccines into room-temperature-stable powders, making distribution simpler, faster, and more equitable. This innovative delivery formulation is being applied across multiple diseases.
Neglected Diseases Initiative
We’re advancing adjuvant-formulated vaccines for neglected diseases often overlooked by commercial R&D—including:
- Malaria
- Leishmaniasis
- Leprosy
- Schistosomiasis
Our goal: to deliver affordable, durable protection to those most at risk.
Get in touch
Our Model in Action
- Developed in collaboration with global health leaders, local ministries, and academic researchers
- Built for scalability in real-world, low-resource environments
- Powered by AAHI’s integrated platform of adjuvants, vaccine formulations, and delivery science
We don’t just create new vaccines. We reimagine how they’re made, distributed, and delivered—to close the global health gap.
Join Our Mission
